Rinvoq and Signifor (Pasireotide Extended-Release Injection)
Determining the interaction of Rinvoq and Signifor (Pasireotide Extended-Release Injection) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased upadacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 70% and 75%, respectively. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased. MANAGEMENT: Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. References "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.
Professional:MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased upadacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 70% and 75%, respectively. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.
MANAGEMENT: Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy.
- "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.
Generic Name: pasireotide
Brand name: Signifor, Signifor LAR
Synonyms: Signifor, Signifor Injection
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Rinvoq-Signifor (Pasireotide Injection)
- Rinvoq-Signifor Injection
- Rinvoq-Signifor LAR
- Rinvoq-Signifor LAR Injection
- Rinvoq-Siklos
- Rinvoq-Siladryl Allergy
- Signifor (Pasireotide Extended-Release Injection)-Riociguat
- Signifor (Pasireotide Extended-Release Injection)-Riomet
- Signifor (Pasireotide Extended-Release Injection)-Riomet Oral Suspension
- Signifor (Pasireotide Extended-Release Injection)-Risankizumab
- Signifor (Pasireotide Extended-Release Injection)-Risankizumab-rzaa topical
- Signifor (Pasireotide Extended-Release Injection)-Risedronate